(R)-1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperidin-4-yl 2-aminoacetate | 1619923-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (R)-1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperidin-4-yl 2-aminoacetate
• 英文别名: [1-[(3R)-3-[4-[[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-4-methylsulfonyl-1-propan-2-ylpyrrol-3-yl]-5-fluorophenyl]piperazin-1-yl]phenyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperidin-4-yl] 2-aminoacetate
• CAS: 1619923-24-8
• 化学式: C₅₅H₆₂ClF₄N₇O₈S₄
• 分子量: 1188.85
• InChiKey: DLMODILYSMKKFE-VZUYHUTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  79
• 可旋转键数：
  21
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  244
• 氢给体数：
  3
• 氢受体数：
  19

反应信息

• 作为产物：
  描述：

  N-[4-[4-[3-[2-(4-Chlorophenyl)-5-methyl-1-(1-methylethyl)-4-(methylsulfonyl)-1H-pyrrol-3-yl]-5-fluorophenyl]-1-piperazinyl]phenyl]-4-[[(1R)-3-(4-hydroxy-1-piperidinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoro-methyl)sulfonyl]-benzenesulfonamide 、 FMOC-甘氨酸羟基琥珀酰亚胺酯 在 二乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 以83 mg的产率得到(R)-1-(3-(4-(N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperidin-4-yl 2-aminoacetate
  参考文献：
  名称：

  BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME

  摘要：

  抑制剂Bcl-2/Bcl-xL及含有该抑制剂的组合物已被披露。还披露了在治疗需要抑制Bcl-2/Bcl-xL以获益的疾病和状况中使用Bcl-2/Bcl-xL抑制剂的方法，如癌症。

  公开号：

  US20140199234A1

文献信息

• Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US11491168B2

  公开（公告）日：2022-11-08

  The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

  本公开提供了一种药物组合物，其包含 Bcl-2/Bcl-xL 抑制剂、化疗剂和药学上可接受的载体。本公开还提供了一种治疗癌症的方法，包括向有需要的受试者单独施用治疗有效量的Bcl-2/Bcl-xL抑制剂或与治疗有效量的化疗剂联合施用。本公开还提供了将 Bcl-2/Bcl-xL 抑制剂和化疗剂组合用于制造抗肿瘤药物的方法。在本公开中，Bcl-2/Bcl-xL 抑制剂与化疗药物联合使用可显著增强抗肿瘤效果。
• BCL-2BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Regents of The University of Michigan

  公开号：EP2945940A1

  公开（公告）日：2015-11-25
• COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US20200222393A1

  公开（公告）日：2020-07-16

  Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bcl-2/Bcl-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).
• COMBINATION OF BCL-2/BCL-XL INHIBITORS AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US20200297743A1

  公开（公告）日：2020-09-24

  The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.
• COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES
  申请人：ASCENTAGE PHARMA (SUZHOU) CO., LTD.

  公开号：US20220143039A1

  公开（公告）日：2022-05-12

  Provided herein is a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. Provided herein is also the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.